智通财经APP讯，圣诺医药-B(02257)发布截至2024年12月31日止年度业绩，该集团取得收益177.8万美元，研发开支2080.2万美元，同比减少61.75%;公司拥有人应占亏损5138.3万美元，同比减少34.7%;每股亏损0.66美元。
公告称，研发开支减少主要归因于本集团的化学、生产及控制开支、临床试验开支、毒理学研究开支、耗材及临床前试验开支减少。该等减少符合本集团的资源分配策略，将财务资源集中用于开发STP705及STP122G，并放缓其他项目的开发。由于本集团截至2024年12月31日止年度为优化专责团队而进行重组以及中高层员工的薪金调整，导致薪金及其他津贴减少，因此与本集团研发活动有关的董事酬金及员工成本亦有所下降。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.